Latest ACE inhibitors Stories
Heart Healthy for a Lifetime: Medicationdiscountcard.com Focuses on Access to Coupons for Heart-Related Medications During American Heart Month Houston, TX (PRWEB)
- Decision could speed access to LCZ696 for heart failure with reduced ejection fraction patients in the US, reducing total review time from 12 to 8 months(1) EAST HANOVER, N.J., Feb.
- New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus enalapril(1,2) EAST
A recent breakthrough in clinical results with an experimental drug to treat heart failure has shown very promising results.
Dr. Milton Packer and Dr. McMurray will be presenting these results for the first time in the United States at the HFSA Annual Meeting LAS VEGAS, Sept.
DENVER, Sept. 8, 2014 /PRNewswire/ -- Silvergate Pharmaceuticals, Inc.
-- LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing enalapril combined with current treatment
- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) EAST HANOVER, N.J., Aug.
-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF EAST HANOVER, N.J., Aug.